Description
Rtsunate (Artesunate) 100 mg
Rtsunate 100 mg is presented as an artesunate medicine. Artesunate is an antimalarial agent used in the management of malaria caused by susceptible Plasmodium species. The exact trade name could not be independently verified from official sources, so this summary focuses on the verified active ingredient, artesunate.
Active Ingredient and Medicine Class
The active ingredient is artesunate, a semisynthetic artemisinin derivative. It belongs to the antimalarial class and is part of the artemisinin family of medicines. Artesunate is rapidly converted in the body to dihydroartemisinin, its active metabolite.
Established Medical Uses
Artesunate is established as an antimalarial medicine. Official prescribing information supports its use for the initial treatment of severe malaria in adults and children, followed by a complete oral antimalarial regimen. In the broader scientific literature, artesunate has also been studied as an oral treatment for uncomplicated malaria, particularly when used with another antimalarial partner drug.
How It Works
Artesunate acts quickly against malaria parasites in the blood. After conversion to dihydroartemisinin, it damages parasite proteins and membranes through a mechanism linked to the artemisinin endoperoxide structure. This rapid parasite-killing activity helps reduce the number of circulating parasites early in treatment.
Important Safety Information
Known serious hypersensitivity to artesunate, including anaphylaxis, is a contraindication. Official prescribing information also highlights post-treatment hemolysis, in which red blood cells break down after therapy and may sometimes be severe enough to require transfusion. Serious hypersensitivity reactions have also been reported. Important interaction concerns include reduced antimalarial exposure or efficacy with some medicines, including nevirapine, ritonavir, and strong UGT inducers such as rifampin, carbamazepine, and phenytoin. Pregnancy is a special situation: official information notes that treatment should not be delayed when artesunate is needed for severe malaria.
Possible Side Effects
Reported adverse effects include hemolytic anemia after treatment, hypersensitivity reactions, and anaphylaxis. In clinical use for severe malaria, other reported reactions have included jaundice, hemoglobinuria, and acute kidney injury requiring dialysis. Scientific studies of oral artesunate have also described generally good tolerability, but adverse effects can vary with the disease being treated and the partner medicine used.
Scientific Evidence
Peer-reviewed studies and reviews support artesunate as a fast-acting antimalarial medicine. Clinical and review literature shows rapid parasite clearance, and comparative studies in severe malaria have found artesunate to be more effective than quinine in major outcomes. Reviews of oral artesunate also note that it can be effective in uncomplicated malaria, but monotherapy is vulnerable to recrudescence and resistance concerns, which is why artesunate is commonly discussed as part of combination treatment strategies rather than as a stand-alone long-course solution.
Medical Information Notice
This educational summary is based on sources available at the time of review. It does not replace the official patient leaflet, product-specific prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration — Artesunate for Injection, full prescribing information. View official prescribing information
- World Health Organization — WHO guidelines for malaria. View official guideline
- Yobouet Ines Kouakou et al. Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. International Journal of Infectious Diseases, 2019. View scientific article
- L B Barradell et al. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs, 1995. View scientific article
